Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

2018 - PANAO Practical Application of New Agents in Oncology


Cancer remains a leading cause of death in the country. Educating healthcare professionals about newly available agents in oncology is critical. Information on new immunotherapies will be available, as well as a discussion of new clinical studies for anticancer agents. 

There will also be a focus on the numerous new immune targets and immunotherapies that have been approved over the last several years, as well as those that are likely to be approved. Several world-renowned and local speakers will discuss how to incorporate these agents into standard clinical practice, providing guidance to the front-line clinicians, nurses, and pharmacists regarding current or projected appropriate use of these therapeutics.

 


 
 
This site is set up to facilitate Pharmacy CPE evaluations to complete and receive CPE credit.  After registering, please complete the evaluations for the sessions you attended.  Credit will be automatically sent to your NABP e-profile which is set up under the individual account.
 
 

Date: Feb 2, 2018 05:00 PM - Feb 3, 2018 05:00 PM

Fee

$0.00

CE Hours

10.50

CE Units

1.050

Registration closes on Apr 01, 2018 11:30 PM

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
 

Co-Sponsor(s)

UT Health San Antonio Cancer Center

Requirements for CE Credit

The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This two-day activity is approved for 1.050 CEUs (10.50 contact hours) of continuing education credit, with a possibility to receive 8.50 if all sessions and one grouping of concurrent sessions are attended.   In order to receive 8.50 contact hours of CE credit, the participant must attend/participate in all sessions of the live program, and complete the online evaluations for each activity attended.  The online evaluations must be completed on/before April 1, 2018 to earn CPE credit for participation in the conference.  Evaluations completed after April 1 will not be awarded credit.

 

 

Registration closes on Apr 01, 2018 at 11:30 PM

Registration Closed  

Precision Oncology/Hematology: Integration into Clinical Practice
  1. Define Personalized Medicine and related terms
  2. Identify clinical, demographic, and molecular variables that influence personalized medicine
  3. List examples of gene/drug pairs for the clinical application of pharmacogenomics
Interactive discussion with panel and audience Panelists:
  • John G. Kuhn, PharmD
  • Howard McLeod, PharmD
  • Ruben Mesa, MD
  • Miguel Villalona-Calero, MD

Speaker(s)/Author(s)

Howard McLeod, PharmD
Moffitt Cancer Center

Activity Number

0067-9999-18-001-L01-P
Date: 02/02/18
Time: 06:30 PM - 08:00 PM

CE Hours

1.50
Registration Closed  

Registration closes on Apr 01, 2018 at 11:30 PM

Registration Closed  

DNA repair as a target in cancer patients and its interface with immunotherapy
  1. Learn to differentiate between mechanisms of DNA repair and implications in cancer risk.
  2. Understand the concept of synthetic lethality and rationale behind the use of PARP inhibitor in patients with inherited homologous recombination repair deficiency.
  3. Learn about immune check point inhibitors and the first tissue agnostic FDA approval indication for an anticancer agent.

Speaker(s)/Author(s)

Miguel Villalona-Calero, MD
Miami Cancer Institute, Baptist Health

Activity Number

0067-9999-18-002-L01-P
Date: 02/03/18
Time: 08:00 AM - 09:00 AM

CE Hours

1.00
Registration Closed  

Registration Closed  

New Agents for Myeloproliferative Neoplasms
  1. Understand the additional JAK inhibitors in development and their likely role in care of MPN patients
  2. Understand the data from new phase 3 trials of interferon use in polycythemia vera and essential thrombocythemia and know how these agents should be used in practice
  3. Understand new pathways being targeted to expand the breadth and depth of response for MPN patients

Speaker(s)/Author(s)

Ruben A. Mesa, MD
UT Health Cancer Center

Activity Number

0067-9999-18-003-L01-P
Date: 02/03/18
Time: 09:00 AM - 10:00 AM

CE Hours

1.00
Registration Closed  

Registration Closed  

NOTE: This is a Concurrent Session: Clinical Track
 
PARP inhibitor, Immuno-therapeutics, Immune Checkpoint Inhibitor
  1. Define PARP inhibitor, Immuno-therapeutics, Immune Checkpoint Inhibitor
  2. Identify potential new treatment strategies
  3. Identify new combination treatments with PARP inhibitors, immune-therapeutics and immune checkpoint inhibitors and how  these have changed in the past 5 years.

Speaker(s)/Author(s)

Kathy Mishaw, MSN, RN-BC, OCN, AOCN
UT MD Anderson Cancer Center

Activity Number

0067-9999-18-004-L01-P
Date: 02/03/18
Time: 10:30 PM - 11:15 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

NOTE: This is a Concurrent Session: Clinical Track
 
Safe Handling of Chemo/Bio/Immunotherapy, USP800 and Immunotherapy
1. Discuss the current research on hazardous drug exposure in healthcare settings.
2. Summarize the requirements of USP <800>.
3. Review the role of Closed System Transfer Devices (CSTDs) in preventing hazardous drug exposure.

Speaker(s)/Author(s)

Seth Eisenberg, RN, OCN
Seattle Cancer Care Alliance

Activity Number

0067-9999-18-005-L05-P
Date: 02/03/18
Time: 11:15 AM - 12:00 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

NOTE: This is a Concurrent Session: Clinical Track
 
Practical Implementation of USP800 in Community Oncology Practices
  1. Understand how UPS800 will increase protection for personnel
  2. Identify containment controls
  3. Describe decontamination, cleaning and disinfection in hazardous drug sterile compounding environments

Speaker(s)/Author(s)

Ivan Reveles, PharmD, M.S., BCPS
UT Health Cancer Center

Activity Number

0067-9999-18-006-L07-P
Date: 02/03/18
Time: 12:00 AM - 12:30 PM

CE Hours

0.50
Registration Closed  

Registration Closed  

NOTE: This is a Concurrent Session: Transitional Trials Track
 
Best of 2017: Precision medicine papers
  1. Have an idea of what are the latest trends in precision oncology
  2. Identify potential new treatment strategies
  3. Identify complementary pathways and approaches

Speaker(s)/Author(s)

Georgios K. Fotopoulos, MD
UT Health Cancer Center

Activity Number

0067-9999-18-007-L01-P
Date: 02/03/18
Time: 10:30 AM - 11:15 AM

CE Hours

0.75
Registration Closed  

Registration Closed  

NOTE: This is a Concurrent Session: Transitional Trials Track
 
New options for acute leukemia: From FLT3 inhibitors to CAR-T cells
  1. Be aware of the expanding array of targeted treatment options for acute myeloid and lymphoblastic leukemias.
  2. Recognize the specific AML mutations for which targeted therapy is currently available.
  3. Identify patients with ALL who are potential candidates for CAR-T cell therapy.

Speaker(s)/Author(s)

Matthew J. Butler, MD
UT Health San Antonio

Activity Number

0067-9999-18-008-L01-P
Date: 02/03/18
Time: 11:15 AM - 12:00 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

NOTE: This is a Concurrent Session: Transitional Trials Track
 
Targeting P13K- Delta in Lymphomas
1. Discuss the current research on targeting P13K – Delta in Lymphomas
2. Summarize the treatment strategies targeting P13K – Delta in Lymphomas
3. Have increased knowledge regarding research data regarding P13K – Delta in Lymphomas

Speaker(s)/Author(s)

Adolfo Enrique Diaz-Duque, MD
UT Health San Antonio

Activity Number

0067-9999-18-009-L01-P
Date: 02/03/18
Time: 12:00 PM - 12:30 PM

CE Hours

0.50
Registration Closed  

Registration Closed  

Hope is the thing with feathers: Ethics and Phase I Cancer Research
  1. Review the published findings of a descriptive study to characterize disclosure and understanding during the informed consent process for the participation of children in Phase I cancer studies.
  2. Articulate the compelling ethical questions and understand the dynamics of hope that arise in this context where the goals of research and the goals of patient care may compete.
  3. Suggest ways to improve informed consent for Phase I cancer trials.

Speaker(s)/Author(s)

Eric Kodish, MD
Cleveland Clinic Foundation

Activity Number

0067-9999-18-010-L01-P
Date: 02/03/18
Time: 01:30 PM - 02:30 PM

CE Hours

1.00
Registration Closed  

Registration Closed  

Bucket and Baskets: How is Precision Medicine changing drug development?
  1. Define Precision Medicine
  2. List examples of how precision medicine is changing drug development.
  3. Discuss how drug development could potentially change precision medicine

Speaker(s)/Author(s)

Howard Burris, MD
Sarah Cannon Research Institute

Activity Number

0067-9999-18-011-L01-P
Date: 02/03/18
Time: 02:30 PM - 03:30 PM

CE Hours

1.00
Registration Closed  

Registration Closed  

Choosing palliative care in the treatment of advanced cancer
  1. Define palliative care and review current evidence based practice guidelines in patient care
  2. Identify opportunities to integrate palliative care in standard oncology through case discussions
  3. Describe unique challenges in clinical trial settings for transitions to palliative services through case discussion examples.

Speaker(s)/Author(s)

Sherri Rauenzahn Cervantez, MD
UT Health Cancer Center

Activity Number

0067-9999-18-012-L01-P
Date: 02/03/18
Time: 03:45 PM - 04:45 PM

CE Hours

1.00
Registration Closed